Zenas BioPharma, Inc. Common Stock Financial Flexibility Index
Zenas BioPharma, Inc. Common Stock financial flexibility index. Zenas BioPharma, Inc. Common Stock (ZBIO) has a Financial Flexibility Index of -0.06x as of June 2026. Free cash flow of $-27.24 Million (operating CF $-57.24 Million minus capex $30.00 Million) represents 0% of total liabilities ($454.59 Million). See Zenas BioPharma, Inc. Common Stock (ZBIO) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Zenas BioPharma, Inc. Common Stock (2022–2025)
Financial flexibility index of Zenas BioPharma, Inc. Common Stock from 2022 to 2025. Historical Financial Flexibility Index trend for Zenas BioPharma, Inc. Common Stock across 4 annual periods. Check Zenas BioPharma, Inc. Common Stock (ZBIO) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Zenas BioPharma, Inc. Common Stock Financial Flexibility Index by Year (2022–2025)
Zenas BioPharma, Inc. Common Stock financial flexibility index by year from 2022 to 2025. Year-by-year free cash flow to debt coverage for Zenas BioPharma, Inc. Common Stock. For the full cash flow conversion analysis, see cash efficiency ratio of Zenas BioPharma, Inc. Common Stock.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -1.22x | $-172.31 Million | $-172.33 Million | $141.50 Million | ▲ +41.4% |
| 2024 | -2.08x | $-119.54 Million | $-119.67 Million | $57.51 Million | ▼ -1902.2% |
| 2023 | -0.10x | $-30.51 Million | $-30.53 Million | $293.90 Million | ▲ +56.3% |
| 2022 | -0.24x | $-63.45 Million | $-65.65 Million | $266.87 Million | — |